Recent research from the Memorial Sloan Kettering Cancer Center highlights the critical prognostic marker of T cell spatial organization in predicting outcomes for patients with stage III colorectal cancer. Integrating spatial and biological biomarkers could refine risk stratification and lead to more personalized treatment strategies, potentially contributing to the development of targeted therapies in colorectal cancer.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
